Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE®

Important Community Notice from the Hemophilia Foundation of Maryland Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant

Read More »
Hemophilia Foundation of Maryland (HFM)

13 Class Court Parkville, MD 21234

HFM Family Events